logo

Mirati Therapeutics, Inc. posts $7.17 million revenue in quarter ended Mar 31, 2023

By USInMinutes - May 10, 2023, 01:47 AM ET
Last Updated - Jul 18, 2023, 03:32 PM EDT
Mirati Therapeutics, Inc. posts $7.17 million revenue in quarter ended Mar 31, 2023

Key fundamental financials
  • loss of $184.59 million
  • Revenue of $7.17 million

Mirati Therapeutics, Inc. [MRTX] has reported $184.59 million loss for the fiscal quarter ending Mar 31, 2023.

Revenue for the quarter was $7.17 million with operating income of $193.82 million.

The Sandiego, California (CA)-based company operating in the pharmaceutical preparations sector has total shareholders equity of $862.63 million.

Also read:

This is a developing story. Click here to receive updates.
------------
NewsInMinutes, an offering of 10kInfo, Inc., brings you news on the latest regulatory filings. Subscribe to additional news alerts here.
Sponsored
Sponsored
Sponsored
Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024